论文部分内容阅读
β-阻滞剂在临床上已广泛用于心肌梗塞(MI)患者,并取得了肯定的疗效。据Wengex等最近统汁,在过去10年内,对无并发症的急性心肌梗塞(AMI)患者,在一般医师、内科医师及心脏科医师中常规应用β-阻滞剂者各占32-38％;出院后常规应用者约占前一数字的1/3。尽管研究还在继续,但大量临床实践证明,β-阻滞剂的问世已为MI的临床治疗提供了新的有价值的途径。本文拟就β-阻滞剂防治MI的药理基础及应用问题作一讨论,以供临床医师参考。
Beta-blockers have been widely used clinically in patients with myocardial infarction (MI), and achieved a positive effect. According to Wengex et al., Recently, β-blockers were commonly used by 32% to 38% of general practitioners, physicians and cardiologists, respectively, in patients with uncomplicated acute myocardial infarction (AMI) in the past 10 years. ; Conventional users after discharge accounted for about 1/3 of the previous figure. Although the research continues, a large number of clinical trials have proved that the advent of β-blockers has provided a new and valuable approach for the clinical treatment of MI. This article intends to β-blocker on the prevention and treatment of MI’s pharmacological basis and application of a discussion for the clinician’s reference.